Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
Animals
Biomarkers, Tumor
/ genetics
Cell Line, Tumor
Cytokines
/ metabolism
Female
Galectin 1
/ genetics
Gene Expression Regulation, Neoplastic
Genetic Heterogeneity
Glioblastoma
/ genetics
Humans
Immunogenetic Phenomena
Immunosuppression Therapy
Macrophages
/ metabolism
Mice
Myeloid-Derived Suppressor Cells
/ metabolism
Neoplasm Transplantation
Prognosis
Software
Tumor Microenvironment
Up-Regulation
LGALS1
glioblastoma
immunosuppression
microenvironment
prognosis
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
12
09
2018
revised:
06
12
2018
accepted:
20
12
2018
pubmed:
8
1
2019
medline:
2
11
2019
entrez:
8
1
2019
Statut:
ppublish
Résumé
Mutualistic and dynamic communication between tumour cells and the surrounding microenvironment accelerates the initiation, progression, chemoresistance and immune evasion of glioblastoma (GBM). However, the immunosuppressive mechanisms of GBM has not been thoroughly elucidated to date. We enrolled six microenvironmental signatures to identify glioma microenvironmental genes. The functional enrichment analysis such as ssGSEA, ESTIMATE algorithm, Gene Ontology, Pathway analysis is conducted to discover the potential function of microenvironmental genes. In vivo and in vitro experiments are used to verify the immunologic function of LGALS1 in GBM. We screen eight glioma microenvironmental genes from glioma databases, and discover a key immunosuppressive gene (LGALS1 encoding Galectin-1) exhibiting obviously prognostic significance among glioma microenvironmental genes. Gliomas with different LGALS1 expression have specific genomic variation spectrums. Immunosuppression is a predominate characteristic in GBMs with high expression of LGALS1. Knockdown of LGALS1 remodels the GBM immunosuppressive microenvironment by down regulating M2 macrophages and myeloid-derived suppressor cells (MDSCs), and inhibiting immunosuppressive cytokines. Our results thus implied an important role of microenvironmental regulation in glioma malignancy and provided evidences of LGALS1 contributing to immunosuppressive environment in glioma and that targeting LGALS1 could remodel immunosuppressive microenvironment of glioma.
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Galectin 1
0
LGALS1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-530Informations de copyright
© 2019 UICC.